CEO Mattias Perjos credited the company's performance to successful product launches and operational efficiency. Acute Care Therapies saw broad gains, while the Sterile Transfer category achieved double-digit growth. Excluding the impact of the tariff refund and currency fluctuations, the adjusted EBITA margin stood at 15.2%, reflecting steady productivity improvements and favorable product mix.
Getinge Reports Strong Q2 2026 Growth Driven by Profitability Gains
A windfall of SEK 336 million from a tariff refund helped propel Getinge to a 17.6% adjusted EBITA margin for the second quarter of 2026. Despite ongoing geopolitical headwinds affecting the pharmaceutical sector, the Swedish medical technology firm reported a 4.6% organic increase in net sales.
Innovation remains a cornerstone of the company’s strategy, evidenced by the release of new endoscopic vessel harvesting technology and automated endoscope reprocessing systems. In June, the company reached a regulatory milestone by submitting a 510(k) application for its Cardiosave intra-aortic balloon pump to the FDA. To bolster its market position, Getinge also acquired the UK-based distributor Pennamed and opened a new digital perioperative innovation center in Hamburg. Given current customer demand, leadership maintains its forecast for 3–5% organic sales growth for the full year.
Comments (0)
No comments yet. Be the first!